222 related articles for article (PubMed ID: 31008727)
1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
[TBL] [Abstract][Full Text] [Related]
2. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
[TBL] [Abstract][Full Text] [Related]
7. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Colombo N
Future Oncol; 2017 Oct; 13(23s):23-29. PubMed ID: 29020821
[TBL] [Abstract][Full Text] [Related]
8. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J; Alfaro V; González-Martín A
Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
11. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
12. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Colombo N
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
[TBL] [Abstract][Full Text] [Related]
16. Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
Lorusso D; González-Martín A; Ray-Coquard I
Future Oncol; 2021 Jan; 17(3s):9-19. PubMed ID: 33353406
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
[TBL] [Abstract][Full Text] [Related]
18. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Colombo N
Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Fisher M; Gore M
Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
[TBL] [Abstract][Full Text] [Related]
20. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
